☆ 4.7 Letter

The Possible Interaction between Receptor Activator of Nuclear Factor Kappa-B Ligand Expressed by Extramammary Paget Cells and its Ligand on Dermal Macrophages

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2015)

Journal

JOURNAL OF INVESTIGATIVE DERMATOLOGY

Volume 135, Issue 10, Pages 2547-2550

Publisher

ELSEVIER SCIENCE INC

DOI: 10.1038/jid.2015.199

Keywords

-

Categories

Dermatology

Funding

Grants-in-Aid for Scientific Research [26461677] Funding Source: KAKEN

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Pharmacology & Pharmacy

Patchouli Alcohol Modulates the Pregnancy X Receptor/Toll-like Receptor 4/Nuclear Factor Kappa B Axis to Suppress Osteoclastogenesis

Qian Lu, Chao Jiang, Jialong Hou, Hao Qian, Feifan Chu, Weiqi Zhang, Mengke Ye, Ziyi Chen, Jian Liu, Hanbing Yao, Jianfeng Zhang, Jiake Xu, Te Wang, Shunwu Fan, Qingqing Wang

Summary: The incidence of osteoporosis is increasing, especially in postmenopausal women. Patchouli alcohol (PA), a natural compound with anti-inflammatory effects, has shown inhibitory effects on osteoclasts and may be a potential treatment for osteoporosis in the future.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Isoliensinine Suppresses Osteoclast Formation Through NF-κB Signaling Pathways and Relieves Ovariectomy-Induced Bone Loss

Huijiang Liu, Ronghe Gu, Qian Huang, Yun Liu, Chong Liu, Shijie Liao, Wenyu Feng, Tianyu Xie, Jinmin Zhao, Jiake Xu, Qian Liu, Xinli Zhan

Summary: This study found that isoliensinine can inhibit the differentiation of osteoclasts and reduce bone loss, showing great potential for treating osteoporosis.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Pharmacology & Pharmacy

Assessment of the Therapeutic Potential of Melatonin for the Treatment of Osteoporosis Through a Narrative Review of Its Signaling and Preclinical and Clinical Studies

Yongchao Zhao, Guoxi Shao, Xingang Liu, Zhengwei Li

Summary: This review comprehensively summarizes the current understanding of melatonin's regulation of bone metabolism, including its effects on mesenchymal stem cells and bone cells to promote bone formation and inhibit bone resorption. Experimental studies and clinical trials have shown that melatonin has a protective effect against osteoporosis and may be a potential novel therapy for this condition.

FRONTIERS IN PHARMACOLOGY (2022)

Add to Collection

Review Endocrinology & Metabolism

Update on the Role of Neuropeptide Y and Other Related Factors in Breast Cancer and Osteoporosis

Shu-ting Lin, Yi-zhong Li, Xiao-qi Sun, Qian-qian Chen, Shun-fa Huang, Shu Lin, Si-qing Cai

Summary: The relationship between breast cancer and osteoporosis is influenced by factors such as estrogen, RANKL, and NPY. Treatment for breast cancer may increase the risk of osteoporosis, while Y1 and Y5 receptors are highly expressed in breast cancer and Y1 and Y2 receptors may affect osteogenic response.

FRONTIERS IN ENDOCRINOLOGY (2021)

Add to Collection

Article Oncology

Dynamic alternations of RANKL/OPG ratio expressed by cementocytes in response to orthodontic-induced external apical root resorption in a rat model

Tingting Wei, Zhiyi Shan, Xin Wen, Ning Zhao, Gang Shen

Summary: The present study investigated the alterations in cementocyte formation in response to orthodontic forces and found that cementocytes responded to the forces by modulating the RANKL/OPG ratio and SOST expression. The biological response of cementocytes played an important role in the mechanotransduction and homeostasis of tooth movement and root resorption.

MOLECULAR MEDICINE REPORTS (2022)

Add to Collection

Review Cell Biology

Roles of osteoprotegerin in endocrine and metabolic disorders through receptor activator of nuclear factor kappa-B ligand/receptor activator of nuclear factor kappa-B signaling

Luodan Zhang, Fa Zeng, Minmin Jiang, Maozhen Han, Binbin Huang

Summary: This article reviews the potential role and therapeutic potential of osteoprotegerin in endocrine and metabolic diseases. It mainly focuses on the effects of osteoprotegerin through the RANKL/RANK/OPG system on various processes such as bone remodeling, vascular calcification, and beta-cell proliferation, providing a comprehensive understanding of osteoprotegerin as a potential drug for these diseases.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2022)

Add to Collection

Article Chemistry, Medicinal

Discovery of PMSA Derivative 11 as a Novel Lead Compound for Therapeutic Treatment of Osteoporosis In Vitro and In Vivo

Zhihao Chen, Karthik Rajan Rajamanickam, Mina Ding, Sang Kyoon Kim, Sang-wook Park, Eunae Kim, Sunwoo Lee, Tae-Hoon Lee

Summary: In this study, we discovered a potent candidate, PMSA derivative 11, for suppressing mature osteoclasts formation in vitro through a TRAP staining assay. The bioactivity of PMSA derivatives was evaluated and 11 showed the most promising bioactivity, with an IC50 value of 322.9 nM, which was 15-fold better than PMSA-3-Ac. Mechanistically, 11 decreased the expression of genes required for osteoclastogenesis by blocking NFATc1 translocation. In vivo investigation demonstrated that 11 prevented excessive osteoclastogenesis-mediated bone loss in ovariectomized osteoporosis mimic mice. These findings highlight the therapeutic potential of 11 as a lead compound for anti-osteoporosis by targeting NFATc1 translocation.

JOURNAL OF MEDICINAL CHEMISTRY (2023)

Add to Collection

Article Pharmacology & Pharmacy

Gamabufotalin Inhibits Osteoclastgenesis and Counteracts Estrogen-Deficient Bone Loss in Mice by Suppressing RANKL-Induced NF-κB and ERK/MAPK Pathways

Kaiqiang Sun, Jian Zhu, Yi Deng, Ximing Xu, Fanqi Kong, Xiaofei Sun, Le Huan, Changzhen Ren, Jingchuan Sun, Jiangang Shi

Summary: Osteolytic bone disease, caused by imbalanced bone homeostasis, can lead to high risk of skeletal fragility and fracture in old and postmenopausal women. Previous studies suggest the potential of traditional Chinese medicine gamabufotalin (CS-6) in inhibiting osteolytic conditions.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Endocrinology & Metabolism

Rhizomelia and Impaired Linear Growth in a Girl with Juvenile Paget Disease: The Natural History of the Condition

Jakob Hoppner, Katja Steff, Felix Lobert, Christoph M. Heyer, Berthold P. Hauffa, Corinna Grasemann

Summary: In ultra-rare bone diseases like JPD, limited information is available on the natural history and growth patterns during childhood. Most affected children receive long-term antiresorptive treatment, primarily with bisphosphonates, which may impact growth. Further studies are needed to understand the effects of antiresorptive treatments on growth and skeletal development in pediatric patients with ultra-rare bone diseases.

HORMONE RESEARCH IN PAEDIATRICS (2021)

Add to Collection

Article Engineering, Biomedical

Studying the mechanical properties of the mandible and injury prediction under the effect of ossification factors

Amirhossein Jafariandehkordi, Alireza Daneshmehr

Summary: This study aims to investigate the effects of chemical factors on bone biological activities and mechanical properties, and assess the possibility of bone injury under uniform mastication pressure in the presence of these chemical factors. The results showed that RANKL and PTH increased the risk of bone injury, while OPG protected the bone from injury.

JOURNAL OF THE MECHANICAL BEHAVIOR OF BIOMEDICAL MATERIALS (2023)

Add to Collection

Article Biochemistry & Molecular Biology

The Influence of Prenatal Fumonisin Exposure on Bone Properties, as well as OPG and RANKL Expression and Immunolocalization, in Newborn Offspring Is Sex and Dose Dependent

Ewa Tomaszewska, Halyna Rudyk, Izabela Swietlicka, Monika Hulas-Stasiak, Janine Donaldson, Marta Arczewska, Siemowit Muszynski, Piotr Dobrowolski, Iwona Puzio, Volodymyr Kushnir, Oksana Brezvyn, Viktor Muzyka, Ihor Kotsyumbas

Summary: The study revealed that exposure of pregnant dams to fumonisins can lead to negative effects on offspring bone metabolism and properties, with impacts depending on dose and sex. Effects were observed in body weight, bone length, and bone mechanical resistance, all linked to alterations in bone metabolism proteins.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Chemistry, Multidisciplinary

Polysaccharides Derived from Drynaria fortunei Attenuated Osteoclast Differentiation Induced by Receptor Activator of Nuclear Factor-κB Ligand by Modulating NFATc1 and c-Fos

Jin Ah Ryuk, Ami Lee, Taesoo Kim, Youn-Hwan Hwang, Hyunil Ha

Summary: Golsebo, the rhizome of Drynaria fortunei, has been traditionally used in Korea for treating various inflammatory conditions, including bone metabolism disorders. This study demonstrates that DFP derived from Golsebo has modulatory effects on the differentiation of bone-marrow-derived macrophages into osteoclasts, suggesting its potential as a nutraceutical candidate for treating bone loss diseases.

APPLIED SCIENCES-BASEL (2023)

Add to Collection

Article Oncology

Capecitabine inhibits epithelial-to-mesenchymal transition and proliferation of colorectal cancer cells by mediating the RANK/RANKL pathway

Minghai Shao, Caiping Jiang, Changhui Yu, Haijian Jia, Yanli Wang, Xinli Mao

Summary: This study investigated the mechanism of action of capecitabine in colorectal cancer cells and found that capecitabine inhibits the proliferation and epithelial-to-mesenchymal transition (EMT) of HT29 cells by suppressing the RANK/RANKL pathway.

ONCOLOGY LETTERS (2022)

Add to Collection

Article Medicine, General & Internal

ETS1 polymorphism rs73013527 in relation to serum RANKL levels among patients with RA

Bin Yang, Limei Luo, Lin Chen, Qian Niu, Junlong Zhang, Huan Xu, Yifeng Wu, Zhuochun Huang

Summary: The study found an association between ETS1 rs73013527 and serum RANKL levels in patients with rheumatoid arthritis (RA), but not with clinical characteristics and laboratory markers in patients. Univariate analysis showed a significant association between the CT/TT genotype of ETS1 rs73013527 and elevated RANKL levels in RA patients, suggesting that ETS1 may be an indirect factor involved in RANKL regulation in RA.

MEDICINE (2021)

Add to Collection

Article Plant Sciences

Expression and Functional Evaluation of Recombinant Anti-receptor Activator of Nuclear Factor Kappa-B Ligand Monoclonal Antibody Produced in Nicotiana benthamiana

Wanuttha Boonyayothin, Sirorut Sinnung, Balamurugan Shanmugaraj, Yoshito Abe, Richard Strasser, Prasit Pavasant, Waranyoo Phoolcharoen

Summary: The study demonstrated the potential of the plant-produced denosumab, expressed transiently in Nicotiana benthamiana using the geminiviral expression system, to inhibit osteoclast differentiation and significantly reduce the number of osteoclasts.

FRONTIERS IN PLANT SCIENCE (2021)

Add to Collection

Letter Dermatology

Demographic and clinical characteristics of extramammary Paget's disease patients in Japan from 2000 to 2019

F. M. Ghazawi, N. Iga, R. Tanaka, Y. Fujisawa, K. Yoshino, C. Yamashita, Y. Yamamoto, T. Fujimura, T. Yanagi, H. Hata, S. Matsushita, M. Le, S. F. Roy, F. Lagace, Y. Ishida, K. Kabashima, A. Otsuka

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

Add to Collection

Article Dermatology

Serum soluble CD163 and proinflammatory chemokines may be biomarkers of the onset of adverse events in dabrafenib plus trametinib combination therapy for advanced melanoma

Ryo Amagai, Taku Fujimura, Yusuke Muto, Yumi Kambayashi, Sadanori Furudate, Kentaro Ohuchi, Takami Okuma, Akira Hashimoto, Setsuya Aiba

Summary: In patients treated with dabrafenib plus trametinib combination therapy, pyrexia is the most common adverse event, potentially correlated with interferon-inducible chemokines. The elevation of sCD163 along with increased levels of CXCL9, CXCL10, and CXCL11 in serum may be associated with the onset of adverse events.

DERMATOLOGIC THERAPY (2021)

Add to Collection

Letter Dermatology

Dabrafenib plus trametinib combination therapy triggered onset of pustulosis palmaris et plantaris in a patient with advanced cutaneous melanoma

Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Ryo Amagai, Takami Okuma, Sadanori Furudate, Akira Hashimoto, Setsuya Aiba

JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Article Dermatology

Possible roles of CXCL13/CXCR5 axis in the development of bullous pemphigoid

Kentaro Ohuchi, Taku Fujimura, Chunbing Lyu, Ryo Amagai, Yusuke Muto, Setsuya Aiba

Summary: The study indicates that CXCL13/CXCR5-mediated migration of Tfh cells plays a role in the development of BP, with CXCL13 levels positively correlated with antibody titers in BP patients. LL37 promotes the secretion of chemokines by M2 macrophages, with CXCL10 acting as a negative regulator in BP development.

JOURNAL OF DERMATOLOGY (2021)

Add to Collection

Letter Dermatology

Nodal anaplastic large cell lymphoma with lymphomatoid papulosis following treatment of initially presumed atopic dermatitis with dupilumab: A case report

Mayuko Amagai, Maki Ozawa, Ryo Amagai, Kentaro Ohuchi, Yusuke Muto, Yumi Kambayashi, Setsuya Aiba, Taku Fujimura

DERMATOLOGIC THERAPY (2022)

Add to Collection

Letter Dermatology

Fulminant type 1 diabetes mellitus triggered by coronavirus disease 2019 vaccination in an advanced melanoma patient given adjuvant nivolumab therapy

Kentaro Ohuchi, Ryo Amagai, Erika Tamabuchi, Yumi Kambayashi, Taku Fujimura

JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Safety and efficacy of bexarotene for Japanese patients with cutaneous T-cell lymphoma: Real-world experience from post-marketing surveillance

Toshihisa Hamada, Akimichi Morita, Hiraku Suga, Hikari Boki, Taku Fujimura, Yoji Hirai, Takatoshi Shimauchi, Chiharu Tateishi, Eiji Kiyohara, Ikko Muto, Hideki Nakajima, Riichiro Abe, Kazuyasu Fujii, Chikako Nishigori, Eiji Nakano, Kentaro Yonekura, Takeru Funakoshi, Masahiro Amano, Tomomitsu Miyagaki, Noriko Makita, Katsunori Manaka, Yoshihito Shimoyama, Makoto Sugaya

Summary: The study suggests that starting bexarotene at 300 mg/m(2) and combining it with photo(chemo)therapy show promising efficacy in treating patients with mycosis fungoides. Further evaluation of low-dose bexarotene plus photo(chemo)therapy efficacy is recommended for future studies.

JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Stromal Factors as a Target for Immunotherapy in Melanoma and Non-Melanoma Skin Cancers

Taku Fujimura

Summary: Tumor-infiltrating leukocytes (TILs) play a crucial role in immunotherapy using ICIs, highlighting the significance of evaluating the characteristics of tumor-associated cells in predicting the efficacy of immune checkpoint inhibitors.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Letter Dermatology

A pediatric case of corticosteroid-resistant erosive pustular dermatosis of scalp-like alopecia treated successfully with oral indomethacin, doxycycline, and topical tacrolimus

Rui Sasaki, Yoshihide Asano, Taku Fujimura

JOURNAL OF DERMATOLOGY (2022)

Add to Collection

Article Dermatology

Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real-world case series

Ryo Amagai, Yumi Kambayashi, Kentaro Ohuchi, Sadanori Furudate, Akira Hashimoto, Yoshihide Asano, Taku Fujimura

Summary: The anti-tumor effects of mogamulizumab and post mogamulizumab therapy were evaluated in 11 cases of CTCL. The best response rate was 45.5% for the total cohort, 50.0% for MF, and 33.3% for PCPTCL-NOS. The objective response rate at 1 month was 45.5% and 27.3% at 4 months. The efficacy rate of etoposide-based therapy was 71.4%.

DERMATOLOGIC THERAPY (2022)

Add to Collection

Article Dermatology

Plasminogen activating inhibitor-1 promotes angiogenesis in cutaneous angiosarcomas

Kentaro Ohuchi, Ryo Amagai, Tetsuya Ikawa, Yusuke Muto, Yuna Roh, Junko Endo, Takeo Maekawa, Yumi Kambayashi, Yoshihide Asano, Taku Fujimura

Summary: PAI-1 expression is associated with vascular tumor progression and angiogenesis in Cutaneous Angiosarcoma (CAS), promoting the expression of angiogenic factors and facilitating the formation of tumor-derived tube networks.

EXPERIMENTAL DERMATOLOGY (2023)

Add to Collection

Article Dermatology

Treatment for taxane-resistant cutaneous angiosarcoma: A multicenter study of 50 Japanese cases

Taku Fujimura, Takeo Maekawa, Hiroshi Kato, Takamichi Ito, Shigeto Matsushita, Koji Yoshino, Yasuhiro Fujisawa, Shoichiro Ishizuki, Kojiro Segawa, Jun Yamamoto, Akira Hashimoto, Yumi Kambayashi, Yoshihide Asano

Summary: This study retrospectively evaluated the efficacy and safety profiles of taxane-switch, eribulin methylate, and pazopanib regimens in second-line chemotherapy for taxane-resistant cutaneous angiosarcoma (CAS) patients. Although there was no significant difference in progression-free survival among the regimens, the incidence of all adverse events, as well as severe G3 or more adverse events, was significantly higher in the eribulin methylate group and pazopanib group compared to the taxane-switch group. Therefore, switching to another taxane should be considered for the treatment of taxane-resistant CAS in second-line therapy based on the safety profiles.

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Allergy

The significance of M1-polarized CD163+ macrophages in acute graft-versus-host disease (GVHD): Possible mechanisms of GVHD in the development of skin lesions

Yusuke Muto, Taku Fujimura, Yumi Kambayashi, Kentaro Ohuchi, Chunbing Lyu, Hitoshi Terui, Masato Mizuashi, Setsuya Aiba, Yoshihide Asano

Summary: The main objective of this study was to determine the main source of IFN-inducible chemokines in the lesional skin of GVHD. Through immunohistochemical staining, it was found that CD163+ macrophages may be the main source of IFN-inducible chemokines, and the chemokine expression patterns on CD163+ macrophages matched the phosphorylation pattern of STATs in epidermal keratinocytes. Therefore, CD163+ macrophages may be a therapeutic target in GVHD.

JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY (2023)

Add to Collection

Article Dermatology

Vogt-Koyanagi-Harada disease-like uveitis after drug therapy including BRAF/MEK inhibitors in melanoma patients with HLA-DRB1*04

Ryo Amagai, Taku Fujimura, Emi Yamazaki, Manami Takahashi, Erika Tamabuchi, Yumi Kambayashi, Akira Hashimoto, Kazuki Hashimoto, Yoshihide Asano

Summary: The combination of BRAF kinase inhibitors and MEK kinase inhibitors may lead to severe VKH disease-like uveitis in melanoma patients with the HLA-DRB1*04 haplotype.

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Dermatology

Efficacy and safety of TM5614 in combination with paclitaxel in the treatment of paclitaxel-resistant cutaneous angiosarcoma: Phase II study protocol

Taku Fujimura, Koji Yoshino, Motoki Nakamura, Hiroshi Kato, Takamichi Ito, Takeo Maekawa, Yasuhiro Fujisawa, Shigeto Matsushita, Ryo Amagai, Emi Yamazaki, Manami Takahashi, Erika Tamabuchi, Akira Hashimoto, Yumi Kambayashi, Naoya Yamazaki, Toshio Miyata, Yoshihide Asano

Summary: This study aims to evaluate the efficacy and safety of PTX in combination with TM5614 (PAI-1 inhibitor) in patients with PTX-resistant CAS. The primary endpoint is the overall response rate at 28 weeks after starting treatment, and the study also includes secondary endpoints and data quality control measures. The study will contribute to the development of novel combination therapy for PTX-resistant CAS patients.

EXPERIMENTAL DERMATOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.